|
Your search returned 250 studies:
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-16602
Conditions: Type 2 Diabetes Mellitus
Location: Altoona, PA
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-28207
Conditions: Type 2 Diabetes Mellitus
Location: Charlotte, NC
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-30076
Conditions: Type 2 Diabetes Mellitus
Location: Roswell, GA
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-30909
Conditions: Type 2 Diabetes Mellitus
Location: Augusta, GA
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-31501
Conditions: Type 2 Diabetes Mellitus
Location: Waycross, GA
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-35661
Conditions: Type 2 Diabetes Mellitus
Location: Muscle Shoals, AL
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-36109
Conditions: Type 2 Diabetes Mellitus
Location: Montgomery, AL
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-37207
Conditions: Type 2 Diabetes Mellitus
Location: Brentwood, TN
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-43551
Conditions: Type 2 Diabetes Mellitus
Location: Perrysburg, OH
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-47714
Conditions: Type 2 Diabetes Mellitus
Location: Evansville, IN
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-49079
Conditions: Type 2 Diabetes Mellitus
Location: Paw Paw, MI
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-59701
Conditions: Type 2 Diabetes Mellitus
Location: Butte, MT
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-60610
Conditions: Type 2 Diabetes Mellitus
Location: Chicago, IL
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-60616
Conditions: Type 2 Diabetes Mellitus
Location: Chicago, IL
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-63031
Conditions: Type 2 Diabetes Mellitus
Location: Florissant, MO
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-70808
Conditions: Type 2 Diabetes Mellitus
Location: Baton Rouge, LA
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-75230
Conditions: Type 2 Diabetes Mellitus
Location: Dallas, TX
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-78229
Conditions: Type 2 Diabetes Mellitus
Location: San Antonio, TX
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-85206
Conditions: Type 2 Diabetes Mellitus
Location: Mesa, AZ
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-90723
Conditions: Type 2 Diabetes Mellitus
Location: Paramount, CA
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-92374
Conditions: Type 2 Diabetes Mellitus
Location: Redlands, CA
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-92801
Conditions: Type 2 Diabetes Mellitus
Location: Anaheim, CA
- 24-week Study Comparing Lixisenatide (AVE0010) to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 - NCT00976937-97504
Conditions: Type 2 Diabetes Mellitus
Location: Medford, OR
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-08750
Conditions: Type 2 Diabetes Mellitus
Location: Sea Girt, NJ
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-08822
Conditions: Type 2 Diabetes Mellitus
Location: Flemington, NJ
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-19146
Conditions: Type 2 Diabetes Mellitus
Location: Philadelphia, PA
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-20852
Conditions: Type 2 Diabetes Mellitus
Location: Rockville, MD
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-23502
Conditions: Type 2 Diabetes Mellitus
Location: Norfolk, VA
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-32835
Conditions: Type 2 Diabetes Mellitus
Location: Orlando, FL
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-37620
Conditions: Type 2 Diabetes Mellitus
Location: Bristol, TN
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-38138
Conditions: Type 2 Diabetes Mellitus
Location: Germantown, TN
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-44060
Conditions: Type 2 Diabetes Mellitus
Location: Mentor, OH
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-48114
Conditions: Type 2 Diabetes Mellitus
Location: Brighton, MI
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-58103
Conditions: Type 2 Diabetes Mellitus
Location: Fargo, ND
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-70808
Conditions: Type 2 Diabetes Mellitus
Location: Baton Rouge, LA
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-71913
Conditions: Type 2 Diabetes Mellitus
Location: Hot Springs, AR
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-72205
Conditions: Type 2 Diabetes Mellitus
Location: Little Rock, AR
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-72653
Conditions: Type 2 Diabetes Mellitus
Location: Mountain Home, AR
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-75093
Conditions: Type 2 Diabetes Mellitus
Location: Plano, TX
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-75230
Conditions: Type 2 Diabetes Mellitus
Location: Dallas, TX
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-77070
Conditions: Type 2 Diabetes Mellitus
Location: Houston, TX
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-77081
Conditions: Type 2 Diabetes Mellitus
Location: Houston, TX
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-85206
Conditions: Type 2 Diabetes Mellitus
Location: Mesa, AZ
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-94520
Conditions: Type 2 Diabetes Mellitus
Location: Concord, CA
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-94904
Conditions: Type 2 Diabetes Mellitus
Location: Greenbrae, CA
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine - NCT00975286-97201
Conditions: Type 2 Diabetes Mellitus
Location: Portland, OR
- 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes - NCT00993473-14222
Conditions: Type 1 Diabetes Mellitus
Location: Buffalo, NY
- 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes - NCT00993473-19104
Conditions: Type 1 Diabetes Mellitus
Location: Philadelphia, PA
- 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes - NCT00993473-19107
Conditions: Type 1 Diabetes Mellitus
Location: Philadelphia, PA
- 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes - NCT00993473-21229
Conditions: Type 1 Diabetes Mellitus
Location: Baltimore, MD
- 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes - NCT00993473-29403
Conditions: Type 1 Diabetes Mellitus
Location: Charleston, SC
- 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes - NCT00993473-77030
Conditions: Type 1 Diabetes Mellitus
Location: Houston, TX
- 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes - NCT00993473-78229
Conditions: Type 1 Diabetes Mellitus
Location: San Antonio, TX
- 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes - NCT00993473-80111
Conditions: Type 1 Diabetes Mellitus
Location: Greenwood Village, CO
- 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes - NCT00993473-92123
Conditions: Type 1 Diabetes Mellitus
Location: San Diego, CA
- 6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes - NCT00993473-95819
Conditions: Type 1 Diabetes Mellitus
Location: Sacramento, CA
- A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes - NCT00457093-93901
Conditions: Type 2 Diabetes
Location: Salinas, CA
- A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care - NCT00939250-75104
Conditions: Type 2 Diabetes - Major Depressive Disorder
Location: Cedar Hill, TX
- A Comprehensive Intervention for Diabetes and Comorbid Depression in Primary Care - NCT00939250-75237
Conditions: Type 2 Diabetes - Major Depressive Disorder
Location: Dallas, TX
- A Culturally Tailored Lifestyle Intervention to Prevent Diabetes in South Asians - NCT01084928-30322
Conditions: Diabetes - Obesity
Location: Atlanta, GA
- A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours - NCT01065948-77025
Conditions: Diabetes
Location: Houston, TX
- A Lifestyle Intervention to Prevent Gestational Diabetes - NCT01141582-01104
Conditions: Gestational Diabetes
Location: Springfield, MA
- A Lifestyle Intervention to Prevent Gestational Diabetes - NCT01141582-01199
Conditions: Gestational Diabetes
Location: Springfield, MA
- A Multicenter, Open Label, Single Dose Study to Evaluate the Effect of Renal Insufficiency on the Pharmacokinetics of SK 0403 - NCT01131091-
Conditions: Type 2 Diabetes Mellitus
Location: Minneapolis, MN
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-01655
Conditions: Type 1 Diabetes Mellitus
Location: Worcester, MA
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-02111
Conditions: Type 1 Diabetes Mellitus
Location: Boston, MA
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-07601
Conditions: Type 1 Diabetes Mellitus
Location: Hackensack, NJ
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-07962
Conditions: Type 1 Diabetes Mellitus
Location: Morristown, NJ
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-10032
Conditions: Type 1 Diabetes Mellitus
Location: New York, NY
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-11501
Conditions: Type 1 Diabetes Mellitus
Location: Mineola, NY
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-13210
Conditions: Type 1 Diabetes Mellitus
Location: Syracuse, NY
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-14642
Conditions: Type 1 Diabetes Mellitus
Location: Rochester, NY
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-15224
Conditions: Type 1 Diabetes Mellitus
Location: Pittsburgh, PA
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-19713
Conditions: Type 1 Diabetes Mellitus
Location: Newark, DE
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-21201
Conditions: Type 1 Diabetes Mellitus
Location: Baltimore, MD
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-23219
Conditions: Type 1 Diabetes Mellitus
Location: Richmond, VA
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-30309
Conditions: Type 1 Diabetes Mellitus
Location: Atlanta, GA
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-32207
Conditions: Type 1 Diabetes Mellitus
Location: Jacksonville, FL
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-32610
Conditions: Type 1 Diabetes Mellitus
Location: Gainsville, FL
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-33155
Conditions: Type 1 Diabetes Mellitus
Location: Miami, FL
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-33606
Conditions: Type 1 Diabetes Mellitus
Location: Tampa, FL
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-38103
Conditions: Type 1 Diabetes Mellitus
Location: Memphis, TN
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-40202
Conditions: Type 1 Diabetes Mellitus
Location: Louisville, KY
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-40536
Conditions: Type 1 Diabetes Mellitus
Location: Lexington, KY
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-44308
Conditions: Type 1 Diabetes Mellitus
Location: Akron, OH
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-48109
Conditions: Type 1 Diabetes Mellitus
Location: Ann Arbor, MI
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-48126
Conditions: Type 1 Diabetes Mellitus
Location: Dearborn, MI
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-52242
Conditions: Type 1 Diabetes Mellitus
Location: Iowa City, IA
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-57701
Conditions: Type 1 Diabetes Mellitus
Location: Rapid City,
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-63110
Conditions: Type 1 Diabetes Mellitus
Location: St. Louis, MO
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-64108
Conditions: Type 1 Diabetes Mellitus
Location: Kansas City, MO
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-67211
Conditions: Type 1 Diabetes Mellitus
Location: Wichita, KS
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-68131
Conditions: Type 1 Diabetes Mellitus
Location: Omaha, NE
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-70118
Conditions: Type 1 Diabetes Mellitus
Location: New Orleans, LA
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-72202
Conditions: Type 1 Diabetes Mellitus
Location: Little Rock, AR
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-72758
Conditions: Type 1 Diabetes Mellitus
Location: Rogers, AR
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-74135
Conditions: Type 1 Diabetes Mellitus
Location: Tulsa, OK
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-76104
Conditions: Type 1 Diabetes Mellitus
Location: Fort Worth, TX
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-78207
Conditions: Type 1 Diabetes Mellitus
Location: San Antonio, TX
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-80045
Conditions: Type 1 Diabetes Mellitus
Location: Aurora, CO
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-83404
Conditions: Type 1 Diabetes Mellitus
Location: Idaho Falls, ID
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-85724
Conditions: Type 1 Diabetes Mellitus
Location: Tucson, AZ
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-89502
Conditions: Type 1 Diabetes Mellitus
Location: Reno, NV
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-92123
Conditions: Type 1 Diabetes Mellitus
Location: San Diego, CA
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-92868
Conditions: Type 1 Diabetes Mellitus
Location: Orange, CA
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-94305
Conditions: Type 1 Diabetes Mellitus
Location: Stanford, CA
- A Phase III Study to Investigate the Impact of Diamyd in Patients Newly Diagnosed With Type 1 Diabetes (USA)- DIAPREVENT - NCT00751842-98101
Conditions: Type 1 Diabetes Mellitus
Location: Seattle, WA
- A Randomized Control Trial Comparing Viaject Versus Humalog in Pumps: Effect on Postprandial Blood Sugars. - NCT01067118-
Conditions: Diabetes Mellitus
Location: Denver, CO
- A Randomized Control Trial Comparing Viaject Versus Humalog in Pumps: Effect on Postprandial Blood Sugars. - NCT01067118-94305
Conditions: Diabetes Mellitus
Location: Stanford, CA
- A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus - NCT01106651-
Conditions: Diabetes Mellitus, Type 2
Location: Wenatchee, WA
- A Study Comparing the Safety, Tolerance, and Efficacy of Various Doses of SK-0403 Versus Placebo and Sitagliptin 100 mg in Patients Not Well-Controlled on Metformin Therapy - NCT01169090-
Conditions: Type 2 Diabetes
Location: Richmond, VA
- A Study for Patients With Type 1 Diabetes - NCT01049412-21204
Conditions: Diabetes Mellitus, Type 1
Location: Baltimore, MD
- A Study for Patients With Type 1 Diabetes - NCT01049412-30309
Conditions: Diabetes Mellitus, Type 1
Location: Atlanta, GA
- A Study for Patients With Type 1 Diabetes - NCT01049412-55416
Conditions: Diabetes Mellitus, Type 1
Location: Minneapolis, MN
- A Study for Patients With Type 1 Diabetes - NCT01049412-66606
Conditions: Diabetes Mellitus, Type 1
Location: Topeka, KS
- A Study for Patients With Type 1 Diabetes - NCT01049412-70006
Conditions: Diabetes Mellitus, Type 1
Location: Metairie, LA
- A Study for Patients With Type 1 Diabetes - NCT01049412-75230
Conditions: Diabetes Mellitus, Type 1
Location: Dallas, TX
- A Study for Patients With Type 1 Diabetes - NCT01049412-78731
Conditions: Diabetes Mellitus, Type 1
Location: Austin, TX
- A Study for Patients With Type 1 Diabetes - NCT01049412-83404
Conditions: Diabetes Mellitus, Type 1
Location: Idaho Falls, ID
- A Study for Patients With Type 1 Diabetes - NCT01049412-91911
Conditions: Diabetes Mellitus, Type 1
Location: Chula Vista, CA
- A Study for Patients With Type 1 Diabetes - NCT01049412-98057
Conditions: Diabetes Mellitus, Type 1
Location: Renton, WA
- A Study for Patients With Type 2 Diabetes - NCT01027871-21204
Conditions: Diabetes Mellitus, Type 2
Location: Baltimore, MD
- A Study for Patients With Type 2 Diabetes - NCT01027871-30309
Conditions: Diabetes Mellitus, Type 2
Location: Atlanta, GA
- A Study for Patients With Type 2 Diabetes - NCT01027871-55416
Conditions: Diabetes Mellitus, Type 2
Location: Minneapolis, MN
- A Study for Patients With Type 2 Diabetes - NCT01027871-66606
Conditions: Diabetes Mellitus, Type 2
Location: Topeka, KS
- A Study for Patients With Type 2 Diabetes - NCT01027871-75230
Conditions: Diabetes Mellitus, Type 2
Location: Dallas, TX
- A Study for Patients With Type 2 Diabetes - NCT01027871-83404
Conditions: Diabetes Mellitus, Type 2
Location: Idaho Falls, ID
- A Study for Patients With Type 2 Diabetes - NCT01027871-96813
Conditions: Diabetes Mellitus, Type 2
Location: Honolulu, HI
- A Study for Patients With Type 2 Diabetes - NCT01027871-98057
Conditions: Diabetes Mellitus, Type 2
Location: Renton, WA
- A Study for Pre-Diabetic Patients With Cholesterol Lowering Drugs - NCT00831129-60637
Conditions: Pre-Diabetes
Location: Chicago, IL
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-03063
Conditions: Diabetes Mellitus, Type 2
Location: Nashua, NH
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-04005
Conditions: Diabetes Mellitus, Type 2
Location: Biddeford, ME
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-04074
Conditions: Diabetes Mellitus, Type 2
Location: Scarborough, ME
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-04401
Conditions: Diabetes Mellitus, Type 2
Location: Bangor, ME
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-06050
Conditions: Diabetes Mellitus, Type 2
Location: New Britain, CT
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-08753
Conditions: Diabetes Mellitus, Type 2
Location: Toms River, NJ
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-11365
Conditions: Diabetes Mellitus, Type 2
Location: Flushing, NY
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-12206
Conditions: Diabetes Mellitus, Type 2
Location: Albany, NY
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-13210
Conditions: Diabetes Mellitus, Type 2
Location: Syracuse, NY
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-15009
Conditions: Diabetes Mellitus, Type 2
Location: Beaver, PA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-17822
Conditions: Diabetes Mellitus, Type 2
Location: Danville, PA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-18711
Conditions: Diabetes Mellitus, Type 2
Location: Wilkes Barre, PA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-19056
Conditions: Diabetes Mellitus, Type 2
Location: Levittown, PA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-19107
Conditions: Diabetes Mellitus, Type 2
Location: Philadelphia, PA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-21075
Conditions: Diabetes Mellitus, Type 2
Location: Elkridge, MD
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-27518
Conditions: Diabetes Mellitus, Type 2
Location: Cary, NC
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-27713
Conditions: Diabetes Mellitus, Type 2
Location: Durham, NC
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-28557
Conditions: Diabetes Mellitus, Type 2
Location: Morehead City, NC
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-28803
Conditions: Diabetes Mellitus, Type 2
Location: Asheville, NC
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-29412
Conditions: Diabetes Mellitus, Type 2
Location: Charleston, SC
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-29572
Conditions: Diabetes Mellitus, Type 2
Location: Myrtle Beach, SC
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-29605
Conditions: Diabetes Mellitus, Type 2
Location: Greenville, SC
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-29651
Conditions: Diabetes Mellitus, Type 2
Location: Greer, SC
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-30308
Conditions: Diabetes Mellitus, Type 2
Location: Atlanta, GA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-32806
Conditions: Diabetes Mellitus, Type 2
Location: Orlando, FL
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-33021
Conditions: Diabetes Mellitus, Type 2
Location: Hollywood, FL
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-33027
Conditions: Diabetes Mellitus, Type 2
Location: Pembroke Pines, FL
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-33316
Conditions: Diabetes Mellitus, Type 2
Location: Fort Lauderdale, FL
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-33401
Conditions: Diabetes Mellitus, Type 2
Location: West Palm Beach, FL
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-38119
Conditions: Diabetes Mellitus, Type 2
Location: Memphis, TN
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-42431
Conditions: Diabetes Mellitus, Type 2
Location: Madisonville, KY
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-43015
Conditions: Diabetes Mellitus, Type 2
Location: Delaware, OH
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-43210
Conditions: Diabetes Mellitus, Type 2
Location: Columbus, OH
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-43551
Conditions: Diabetes Mellitus, Type 2
Location: Perrysburg, OH
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-44122
Conditions: Diabetes Mellitus, Type 2
Location: Cleveland, OH
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-45242
Conditions: Diabetes Mellitus, Type 2
Location: Cincinnati, OH
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-45439
Conditions: Diabetes Mellitus, Type 2
Location: Dayton, OH
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-47591
Conditions: Diabetes Mellitus, Type 2
Location: Vincennes, IN
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-48302
Conditions: Diabetes Mellitus, Type 2
Location: Bloomfield Hills, MI
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-48503
Conditions: Diabetes Mellitus, Type 2
Location: Flint, MI
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-60012
Conditions: Diabetes Mellitus, Type 2
Location: Crystal Lake, IL
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-61615
Conditions: Diabetes Mellitus, Type 2
Location: Peoria, IL
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-63141
Conditions: Diabetes Mellitus, Type 2
Location: St Louis, MO
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-66606
Conditions: Diabetes Mellitus, Type 2
Location: Topeka, KS
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-70112
Conditions: Diabetes Mellitus, Type 2
Location: New Orleans, LA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-75231
Conditions: Diabetes Mellitus, Type 2
Location: Dallas, TX
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-76014
Conditions: Diabetes Mellitus, Type 2
Location: Arlington, TX
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-78258
Conditions: Diabetes Mellitus, Type 2
Location: San Antonio, TX
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-78404
Conditions: Diabetes Mellitus, Type 2
Location: Corpus Christi, TX
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-78731
Conditions: Diabetes Mellitus, Type 2
Location: Austin, TX
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-79925
Conditions: Diabetes Mellitus, Type 2
Location: El Paso, TX
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-83404
Conditions: Diabetes Mellitus, Type 2
Location: Idaho Falls, ID
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-83646
Conditions: Diabetes Mellitus, Type 2
Location: Meridian, ID
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-83702
Conditions: Diabetes Mellitus, Type 2
Location: Boise, ID
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-84088
Conditions: Diabetes Mellitus, Type 2
Location: West Jordan, UT
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-84403
Conditions: Diabetes Mellitus, Type 2
Location: Ogden, UT
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-84790
Conditions: Diabetes Mellitus, Type 2
Location: St. George, UT
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-85028
Conditions: Diabetes Mellitus, Type 2
Location: Phoenix, AZ
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-85395
Conditions: Diabetes Mellitus, Type 2
Location: Goodyear, AZ
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-90723
Conditions: Diabetes Mellitus, Type 2
Location: Paramount, CA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-91345
Conditions: Diabetes Mellitus, Type 2
Location: Mission Hills, CA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-91950
Conditions: Diabetes Mellitus, Type 2
Location: National City, CA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-92056
Conditions: Diabetes Mellitus, Type 2
Location: Oceanside, CA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-92201
Conditions: Diabetes Mellitus, Type 2
Location: Indio, CA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-92780
Conditions: Diabetes Mellitus, Type 2
Location: Tustin, CA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-93534
Conditions: Diabetes Mellitus, Type 2
Location: Lancaster, CA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-93720
Conditions: Diabetes Mellitus, Type 2
Location: Fresno, CA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-93940
Conditions: Diabetes Mellitus, Type 2
Location: Monterey, CA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-94520
Conditions: Diabetes Mellitus, Type 2
Location: Concord, CA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-94583
Conditions: Diabetes Mellitus, Type 2
Location: San Ramon, CA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-94904
Conditions: Diabetes Mellitus, Type 2
Location: Greenbrae, CA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-95661
Conditions: Diabetes Mellitus, Type 2
Location: Roseville, CA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-96813
Conditions: Diabetes Mellitus, Type 2
Location: Honolulu, HI
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-97330
Conditions: Diabetes Mellitus, Type 2
Location: Corvallis, OR
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-97401
Conditions: Diabetes Mellitus, Type 2
Location: Eugene, OR
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-97701
Conditions: Diabetes Mellitus, Type 2
Location: Bend, OR
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-98405
Conditions: Diabetes Mellitus, Type 2
Location: Tacoma, WA
- A Study in Patients With Type 2 Diabetes Mellitus - NCT01064687-99202
Conditions: Diabetes Mellitus, Type 2
Location: Spokane, WA
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-03063
Conditions: Diabetes Mellitus, Type 2
Location: Nashua, NH
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-14609
Conditions: Diabetes Mellitus, Type 2
Location: Rochester, NY
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-15009
Conditions: Diabetes Mellitus, Type 2
Location: Beaver, PA
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-15905
Conditions: Diabetes Mellitus, Type 2
Location: Johnstown, PA
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-19056
Conditions: Diabetes Mellitus, Type 2
Location: Levittown, PA
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-23233
Conditions: Diabetes Mellitus, Type 2
Location: Richmond, VA
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-27609
Conditions: Diabetes Mellitus, Type 2
Location: Raleigh, NC
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-30303
Conditions: Diabetes Mellitus, Type 2
Location: Atlanta, GA
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-32822
Conditions: Diabetes Mellitus, Type 2
Location: Orlando, FL
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-33316
Conditions: Diabetes Mellitus, Type 2
Location: Fort Lauderdale, FL
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-35801
Conditions: Diabetes Mellitus, Type 2
Location: Huntsville, AL
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-40217
Conditions: Diabetes Mellitus, Type 2
Location: Louisville, KY
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-48075
Conditions: Diabetes Mellitus, Type 2
Location: Southfield, MI
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-49503
Conditions: Diabetes Mellitus, Type 2
Location: Grand Rapids, MI
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-53051
Conditions: Diabetes Mellitus, Type 2
Location: Menomonee Falls, WI
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-59802
Conditions: Diabetes Mellitus, Type 2
Location: Olympia, WA
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-60031
Conditions: Diabetes Mellitus, Type 2
Location: Gurnee, IL
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-62704
Conditions: Diabetes Mellitus, Type 2
Location: Springfield, IL
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-66606
Conditions: Diabetes Mellitus, Type 2
Location: Topeka, KS
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-78626
Conditions: Diabetes Mellitus, Type 2
Location: Georgetown, TX
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-78749
Conditions: Diabetes Mellitus, Type 2
Location: Austin, TX
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-83404
Conditions: Diabetes Mellitus, Type 2
Location: Idaho Falls, ID
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-85018
Conditions: Diabetes Mellitus, Type 2
Location: Phoenix, AZ
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-90620
Conditions: Diabetes Mellitus, Type 2
Location: Buena Park, CA
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-91505
Conditions: Diabetes Mellitus, Type 2
Location: Burbank, CA
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-92374
Conditions: Diabetes Mellitus, Type 2
Location: Redlands, CA
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-94401
Conditions: Diabetes Mellitus, Type 2
Location: San Mateo, CA
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-97404
Conditions: Diabetes Mellitus, Type 2
Location: Eugene, OR
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-98942
Conditions: Diabetes Mellitus, Type 2
Location: Selah, WA
- A Study in Patients With Type 2 Diabetes Mellitus (AWARD-3) - NCT01126580-99208
Conditions: Diabetes Mellitus, Type 2
Location: Spokane, WA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-14224
Conditions: Type 2 Diabetes
Location: West Seneca, NY
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-15216
Conditions: Type 2 Diabetes
Location: Pittsburgh, PA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-23454
Conditions: Type 2 Diabetes
Location: Virginia Beach, VA
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-27408
Conditions: Type 2 Diabetes
Location: Greensboro, NC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-28209
Conditions: Type 2 Diabetes
Location: Charlotte, NC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-28262
Conditions: Type 2 Diabetes
Location: Charlotte, NC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-29485
Conditions: Type 2 Diabetes
Location: Summerville, SC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-29582
Conditions: Type 2 Diabetes
Location: North Myrtle Beach, SC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-29605
Conditions: Type 2 Diabetes
Location: Greenville, SC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-29621
Conditions: Type 2 Diabetes
Location: Anderson, SC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-29687
Conditions: Type 2 Diabetes
Location: Taylors, SC
- A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) - NCT01137474-30328
Conditions: Type 2 Diabetes
Location: Sandy Springs, GA
|
|